1.40
Erasca Inc stock is traded at $1.40, with a volume of 4.01M.
It is down -3.45% in the last 24 hours and down -2.10% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$1.45
Open:
$1.449
24h Volume:
4.01M
Relative Volume:
2.42
Market Cap:
$396.61M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.7073
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+14.75%
1M Performance:
-2.10%
6M Performance:
-51.05%
1Y Performance:
-43.55%
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Compare ERAS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ERAS
Erasca Inc
|
1.40 | 345.61M | 0 | -125.04M | -122.99M | -0.82 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-26-25 | Initiated | Raymond James | Outperform |
Nov-18-24 | Initiated | Jefferies | Buy |
Mar-11-24 | Initiated | CapitalOne | Overweight |
Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
Oct-11-23 | Initiated | H.C. Wainwright | Buy |
Mar-30-23 | Initiated | Mizuho | Buy |
Feb-24-23 | Initiated | Goldman | Buy |
Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Deutsche Bank AG Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Discover May 2025's Top Penny Stocks - simplywall.st
Bank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Precision Oncology Pioneer Erasca Sets Major Investor Presentations at Jefferies and Goldman Sachs Conferences - Stock Titan
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLC - Defense World
D. E. Shaw & Co. Inc. Has $927,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Northern Trust Corp Boosts Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of “Buy” by Analysts - Defense World
Erasca Inc (NASDAQ: ERAS) Could Pass $5 In One Year Stock Forecast - Stocksregister
Price T Rowe Associates Inc. MD Buys 10,899 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
HC Wainwright Has Positive Forecast for Erasca Q2 Earnings - Defense World
Erasca (ERAS) Target Price Adjusted by Guggenheim Analyst | ERAS Stock News - GuruFocus
FDA clears Erasca’s new cancer drug ERAS-0015 By Investing.com - Investing.com India
Erasca (ERAS) Advances RAS-Targeting Therapies with New Clinical Developments | ERAS Stock News - GuruFocus
Erasca Reports First Quarter 2025 Business Updates and Financial Results - The Manila Times
Erasca, Inc. Advances RAS-Targeting Pipeline with IND Clearances and Extended Cash Runway - Nasdaq
Erasca Advances Two Novel Cancer Drugs to Clinic, Secures 3-Year Cash Runway with $411M - Stock Titan
Erasca Seeks Partner for Naporafenib to Extend Cash Runway - marketscreener.com
Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | - GuruFocus
Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | ERAS Stock News - GuruFocus
FDA clears Erasca’s new cancer drug ERAS-0015 - Investing.com
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway - The Manila Times
Dimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Hsbc Holdings PLC Purchases 10,458 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Tower Research Capital LLC TRC - Defense World
Erasca (ERAS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
MetLife Investment Management LLC Has $283,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca to Present at the Bank of America Securities Health Care Conference - TradingView
Recurrent Glioblastoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Invesco Ltd. Acquires 11,290 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Barclays PLC Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Wells Fargo & Company MN Sells 73,262 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Reaffirms Buy Rating for Erasca (NASDAQ:ERAS) - Defense World
Holdings of Erasca Inc (ERAS) are aligned with the stars - Sete News
Analyze Erasca Inc (NASDAQ: ERAS) Before Investing. - Stocksregister
Erasca Inc (ERAS)’s stock price range in the last year - uspostnews.com
Legal & General Group Plc Buys 64,574 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (ERAS) Showcases Innovative RAS-Targeting Treatments at C - GuruFocus
Erasca presents new RAS-targeting franchise data at AACR meeting - TipRanks
XTX Topco Ltd Purchases Shares of 55,361 Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - The Manila Times
New Cancer Drug Data: Erasca's RAS Inhibitors Show Best-in-Class Potential at AACR 2025 - Stock Titan
Erasca Inc (NASDAQ: ERAS) Shares Are Down -44.22% Year To Date. - Marketing Sentinel
Checking in on Erasca Inc (ERAS) after recent insiders movement - knoxdaily.com
Carclo (LON:CAR) Trading Up 3.1% – Here’s Why - The AM Reporter
Erasca, Inc: Carving A Different Niche In RAS Signaling (NASDAQ:ERAS) - Seeking Alpha
Check out these key findings about Erasca Inc (ERAS) - Sete News
Analytical Overview: Erasca Inc (ERAS)’s Ratios Tell a Financial Story - DWinneX
Erasca Inc (ERAS) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
ERAS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):